Last $44.14 USD
Change Today 0.00 / 0.00%
Volume 0.0
SGEN On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGEN) Snapshot

Open
$44.15
Previous Close
$44.09
Day High
$44.42
Day Low
$43.56
52 Week High
02/28/14 - $55.99
52 Week Low
05/23/14 - $32.35
Market Cap
5.4B
Average Volume 10 Days
717.5K
EPS TTM
$-0.59
Shares Outstanding
123.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEATTLE GENETICS INC (SGEN)

seattle genetics inc (SGEN) Related Businessweek News

View More BusinessWeek News

seattle genetics inc (SGEN) Details

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that has been approved in approximately 35 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company also evaluates approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage ADC programs, including SGN-CD19A for CD19A-positive hematologic malignancies, SGN-CD33A in CD33-positive acute myeloid leukemia, SGN-LIV1A in LIV-1-positive breast cancer, ASG-22ME for treatment of Nectin-4-positive solid tumors, and ASG-15ME for treatment of SLITRK6-positive bladder cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Agensys, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

582 Employees
Last Reported Date: 02/28/14
Founded in 1997

seattle genetics inc (SGEN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $724.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $397.0K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $456.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $383.3K
Executive Vice President of Commercial
Total Annual Compensation: $309.3K
Compensation as of Fiscal Year 2013.

seattle genetics inc (SGEN) Key Developments

Seattle Genetics Initiates Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD70A for Non-Hodgkin Lymphoma and Renal Cell Carcinoma

Seattle Genetics Inc. announced the initiation of a phase 1 clinical trial evaluating SGN-CD70A for CD70-positive relapsed or refractory non-Hodgkin lymphoma (NHL) and metastatic renal cell carcinoma (RCC). SGN-CD70A is a novel antibody-drug conjugate (ADC) targeted to CD70 utilizing the company's newest ADC technology. The phase 1 trial is designed to assess the safety and antitumor activity of SGN-CD70A. The company previously observed single-agent activity, including objective responses, in a phase 1 clinical trial with an initial CD70-targeted ADC called SGN-75 but did not observe enough activity to support further clinical development. To build on that experience, the company developed a next-generation anti-CD70 ADC utilizing its newest technology comprising a highly potent cytotoxic agent, called a pyrrolobenzodiazepine (PBD) dimer, stably linked to a CD70-directed antibody via proprietary site-specific conjugation technology. Preclinical data presented at the 2014 American Association of Cancer Research (AACR) annual meeting demonstrate SGN-CD70A induces targeted cell killing via DNA damage to treated tumors in both RCC and NHL models. The new SGN-CD70A study is a phase 1, open-label, multi-center, dose-escalation clinical trial. The primary endpoints are to estimate the maximum tolerated dose and to evaluate the safety of SGN-CD70A. In addition, the trial will evaluate the antitumor activity and pharmacokinetics in patients with CD70-positive metastatic RCC or relapsed or refractory NHL, including mantle cell lymphoma and diffuse large B-cell lymphoma. The study is designed to evaluate SGN-CD70A administered every three weeks and will enroll approximately 95 patients at multiple centers in the United States.

Seattle Genetics Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year of 2014

Seattle Genetics Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $68.308 million against $73.558 million a year ago. Loss from operations was $17.643 million against $7.009 million a year ago. Net loss was $17.590 million or $0.14 per diluted share against $6.899 million or $0.06 per diluted share a year ago. For the six months, the company reported total revenues of $136.579 million against $130.886 million a year ago. Loss from operations was $34.014 million against $23.396 million a year ago. Net loss was $33.891 million or $0.28 per diluted share against $23.163 million or $0.19 per diluted share a year ago. The company anticipates that 2014 revenues from ADCETRIS net product sales in the U.S. and Canada will be slightly higher than previously anticipated, and are now expected to be in the range of $160 million to $170 million. The company also anticipates that 2014 research and development expenses will be slightly lower than previously anticipated, and are now expected to be in the range of $235 million to $250 million.

Seattle Genetics Inc. to Report Q2, 2014 Results on Jul 31, 2014

Seattle Genetics Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $44.14 USD 0.00

SGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $6.36 USD 0.00
Insys Therapeutics Inc $34.54 USD 0.00
InterMune Inc $73.18 USD 0.00
Medivation Inc $89.44 USD 0.00
Pfizer Ltd/India 1,423 INR -14.95
View Industry Companies
 

Industry Analysis

SGEN

Industry Average

Valuation SGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.8x
Price/Book 24.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit www.seattlegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.